BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19480244)

  • 1. Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years' experience in the Kinki District of Japan (1990-2006).
    Kokawa K; Mikami Y; Sakata H; Oki N; Tanakas T; Yamazaki M; Nakata Y; Umesaki N
    Eur J Gynaecol Oncol; 2009; 30(2):155-61. PubMed ID: 19480244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and survival of borderline ovarian tumors in Rajavithi Hospital between 1979-2006 A.D.
    Sornsukolrat S; Tuipae S
    J Med Assoc Thai; 2012 Sep; 95(9):1141-8. PubMed ID: 23140030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
    Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
    Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Borderline tumors of the ovary.
    Damak T; Ben Hassouna J; Chargui R; Gamoudi A; Hechiche M; Dhieb T; Rahal K
    Tunis Med; 2014 Jun; 92(6):411-6. PubMed ID: 25741843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
    Eichhorn JH; Bell DA; Young RH; Scully RE
    Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
    Leary A; Petrella MC; Pautier P; Duvillard P; Uzan C; Tazi Y; Ledoux F; Gouy S; Morice P; Lhommé C
    Gynecol Oncol; 2014 Jan; 132(1):23-7. PubMed ID: 24219980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
    Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
    Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial ovarian tumors of borderline malignancy.
    Chao TM; Yen MS; Chao KC; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Aug; 58(2):97-102. PubMed ID: 8915111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.
    Camatte S; Morice P; Atallah D; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Castaigne D
    J Am Coll Surg; 2002 Sep; 195(3):332-8. PubMed ID: 12229940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.
    Avril S; Hahn E; Specht K; Hauptmann S; Höss C; Kiechle M; Höfler H; Schmalfeldt B
    Gynecol Oncol; 2012 Dec; 127(3):516-24. PubMed ID: 23000388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
    Gouy S; Arfi A; Maulard A; Pautier P; Bentivegna E; Leary A; Chargari C; Genestie C; Morice P
    Oncologist; 2019 May; 24(5):702-709. PubMed ID: 30201740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.
    Gilks CB; Alkushi A; Yue JJ; Lanvin D; Ehlen TG; Miller DM
    Int J Gynecol Pathol; 2003 Jan; 22(1):29-36. PubMed ID: 12496695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities.
    Kaern J; Tropé CG; Abeler VM
    Cancer; 1993 Mar; 71(5):1810-20. PubMed ID: 8383580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.